Look back at pharma news in two weeks to January 4

6 January 2019

By Barbara Obstoj-Cardwell. Editor

Hope all our readers have had a wonderful festive season, so now welcome back to our review of important news, this time for the two weeks to January 4. Opening the New Year, was Bristol-Myers Squibb’s surprise announcement that it was to acquire fellow USA-based biotech Celgene in a $74 billion cash and share deal. In a rush of pre-year-end US approvals, the Food and Drug Administration cleared Alexion’s Ultomiris for a rare, life-threatening blood cancer. The FDA granted Breakthrough Therapy designation for Roche and Chugai’s satralizumab for a rare disease, and also approved Acorda’s Inbrija for Parkinson’s disease.

Bristol-Myers Squelgene makes its pre-JP Morgan splash

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK